Lurasidone HCl - A Long Term Phase 3 Study of Patients With Chronic Schizophrenia

Completed · Phase 3

Conditions studied: Chronic Schizophrenia

In brief

Lurasidone HCl is a compound being developed for the treatment of schizophrenia. This clinical study is designed to test the hypothesis that lurasidone is effective, tolerable, and safe as compared with quetiapine XR long term among schizophrenic outpatients with chronic schizophrenia.

Key facts

Study ID
NCT00789698
Run by
Sumitomo Pharma America, Inc.
People needed
240
Starts
2008-12-01
Expected to finish
2011-07-01
Last updated by the study team
2015-06-12

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.